A penile implant may be considered for persistent erectile dysfunction when other options are unsuitable or insufficient, or after an informed preference for surgery; assessment integrates clinical context, risk, functional requirements, expectations, and follow-up.
In brief: Candidacy for a penile implant is not established by one diagnosis or characteristic, such as diabetes or previous prostate surgery. The current European Association of Urology (EAU) guideline recommends considering a prosthesis when other treatments are unsuitable or have not worked, or when a person prefers surgery after being fully informed of benefits and harms. The decision rests on specialist urological assessment of the cause and course of erectile dysfunction, previous treatment, surgical risk, ability to operate a device, expectations, and follow-up conditions. [1]
What questions does candidacy assessment answer?
The assessment is broader than whether an operation is technically possible. The clinical team considers erectile function separately from sexual desire, penile sensation, orgasm, and ejaculation. A penile implant principally provides mechanical rigidity for intercourse; it does not directly treat those other functions. The American Urological Association (AUA) emphasises discussing device choices, benefits, burdens, and the effectively irreversible nature of implantation before a decision is made. [2]
History and examination commonly address onset and course, whether previous therapies were used correctly, diabetes and cardiovascular or neurological disease, previous pelvic or prostate surgery, penile curvature or tissue change, medicines, and possible sources of infection. Testing is not identical for everyone; focused examination, laboratory assessment, and any specialised investigation are selected in response to the clinical findings.
Are diabetes or prostate surgery sufficient on their own?
No. Diabetes may contribute to erectile dysfunction and forms part of infection-risk assessment, but the diagnosis does not automatically establish candidacy. Erectile dysfunction after prostate-cancer treatment likewise does not produce an automatic implant decision. Baseline function, treatment received, time since treatment, associated conditions, options already tried, and the individual's goals are considered together.
Active urogenital infection or active skin infection in the surgical region is listed as a contraindication in the official safety information for specified AMS 700 systems. All product-specific contraindications and warnings must be checked in the current instructions for the device that would actually be used. [3]
How are previous treatment options reviewed?
Management may include modification of relevant risk factors, PDE5 inhibitors, vacuum devices, intracavernosal or intra-urethral therapy, and psychosexual support when appropriate. Before a medicine is judged ineffective, practical details such as dose, timing, stimulation, and safe use may need review. Treatment should not be started, stopped, or combined without clinical advice. The erectile dysfunction and penile implant treatment resources provide the wider care context.
How do device categories enter the decision?
Inflatable and malleable implants have different operating and use models. Evaluation is not a technical-feature contest: anatomy, previous surgery, manual dexterity, training needs, concealment expectations, follow-up capacity, and the institution's care pathway all matter. The EAU notes that direct comparative evidence does not establish superiority among manufacturers' implants. Category information therefore cannot create a universal product ranking. [1]
Core elements of an informed decision
- What function the implant is intended to provide—and what it does not change
- How inflatable and malleable systems work and what their use requires
- Infection, bleeding, anaesthetic, mechanical-failure, and revision considerations
- Irreversible change to natural erectile tissue and its effect on other interventional options
- Realistic expectations about length, appearance, sensation, orgasm, and ejaculation
- An individual recovery, device-training, and long-term follow-up plan
An implant is not guaranteed to remain complication-free for life and is not designed as a penile-enlargement procedure. Intended use, warnings, MR conditions, and follow-up information for a specific product must come from its current official documentation.
Practical context for physicians and institutions
A safe implant pathway connects selection, infection and anaesthetic assessment, verification of the correct product and components, operating-room readiness, discharge education, and accessible follow-up if a complication is suspected. Luvi Health's role is not to take over the clinical decision; it is to connect verified product knowledge, technical documentation, and professional processes in a traceable information pathway.
Professional boundary
This resource does not issue a personal candidacy result, product recommendation, or surgical instruction. Diagnosis, treatment sequence, patient and device selection, implantation, and follow-up remain the responsibility of the evaluating specialist physician and qualified healthcare institution.
References
- EAU Guidelines on Sexual and Reproductive Health, Management of Erectile Dysfunction, 2026.
- American Urological Association, Erectile Dysfunction Guideline, penile-prosthesis counselling and treatment options.
- Boston Scientific, AMS 700 Inflatable Penile Prosthesis Prescriptive Information. Current product-specific instructions for use remain controlling.